Tianda Pharmaceuticals Ltd
HKEX:455
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (1.6), the stock would be worth HK$0.11 (11% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.4 | HK$0.1 |
0%
|
| 3-Year Average | 1.6 | HK$0.11 |
+11%
|
| 5-Year Average | 1.5 | HK$0.1 |
+3%
|
| Industry Average | 1.8 | HK$0.12 |
+27%
|
| Country Average | 4.2 | HK$0.29 |
+193%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| HK |
T
|
Tianda Pharmaceuticals Ltd
HKEX:455
|
210.7m HKD | 1.4 | -3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 17.4 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 8.8 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 6.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 7.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 5.9 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 4.2 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 4.3 | 16.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.9 |
| Median | 4.2 |
| 70th Percentile | 9 |
| Max | 31 061 831.6 |
Other Multiples
Tianda Pharmaceuticals Ltd
Glance View
Tianda Pharmaceuticals Ltd. operates as an investment holding company, which engages in the research and development, manufacture and sale of pharmaceutical, biotechnology and healthcare products. The company employs 714 full-time employees The main businesses of the Company include the research and development, production and sales of pharmaceutical, biotechnology and healthcare products. Its products include cardio-cerebrovascular drugs, paediatric drugs, anti-flu and respiratory system drugs, anti-infection drugs, medicines for drug addicts and other pharmaceutical products, as well as healthcare products under the Herb Valley series. The firm operates businesses in Hong Kong, China and Australia.
